Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

77studies shown

Showing 51-75 of 77

TerminatedNCT06514742

A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant

This study has public registry information. It focuses on depression and currently lists study information in Belgium, Brazil, Bulgaria, Finland, Hungary, Poland, Spain, Sweden, and the United States.

DepressionOtherFrom 18 Years to 64 Years

Countries: Belgium, Brazil, Bulgaria, Finland, Hungary, Poland, Spain, Sweden, United States
Sponsor: Janssen Research & Development, LLC
Condition: Depression

View study

CompletedNCT04253327

Distress, Anxiety and Psychosexual Health in BOT

This study is completed. It focuses on anxiety and currently lists study information in Belgium.

AnxietyOtherFrom 18 Years to 100 Years

Countries: Belgium
Sponsor: Universitair Ziekenhuis Brussel
Condition: Anxiety

View study

RecruitingNCT07158684

Surgical COrncerns and Psychological Evaluation of Patients Undergoing Elective Surgery

This study is recruiting. It focuses on anxiety and currently lists participation information in Belgium.

AnxietyOtherOver 18 Years

Countries: Belgium
Sponsor: University Hospital, Antwerp
Condition: Anxiety

View study

TerminatedNCT05211947

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

This study has public registry information. It focuses on schizophrenia and currently lists study information in Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, Lithuania, Malaysia, Mexico, the Netherlands, New Zealand, Norway, the Philippines, Poland, Portugal, Romania, Serbia, Slovakia, South Korea, Spain, Sweden, Taiwan, Turkey, Ukraine, the United Kingdom, and the United States.

SchizophreniaOtherFrom 18 Years to 51 Years

Countries: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Italy, Japan, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Norway, Philippines, Poland, Portugal, Romania, Serbia, Slovakia, South Korea, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States
Sponsor: Boehringer Ingelheim
Condition: Schizophrenia

View study

RecruitingNCT07509125

Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders

This study is recruiting. It focuses on schizophrenia and currently lists participation information in Belgium.

SchizophreniaOtherFrom 18 Years to 90 Years

Countries: Belgium
Sponsor: Universitaire Ziekenhuizen KU Leuven
Condition: Schizophrenia

View study

CompletedNCT04860830

CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

This study is completed. It focuses on schizophrenia and currently lists study information in Argentina, Austria, Belgium, Brazil, Bulgaria, China, Czech Republic, Denmark, Finland, Germany, Lithuania, Mexico, Portugal, Serbia, South Korea, Taiwan, the United Kingdom, and the United States.

SchizophreniaOtherFrom 18 Years to 50 Years

Countries: Argentina, Austria, Belgium, Brazil, Bulgaria, China, Czech Republic, Denmark, Finland, Germany, Lithuania, Mexico, Portugal, Serbia, South Korea, Taiwan, United Kingdom, United States
Sponsor: Boehringer Ingelheim
Condition: Schizophrenia

View study

Active Not RecruitingNCT06945627

Profiling Vulnerability and Resilience for Mental Illness Following Viral Infections

This study is active but not recruiting. It focuses on schizophrenia and currently lists study information in Belgium, Israel, Italy, and Norway.

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: Belgium, Israel, Italy, Norway
Sponsor: Sara Poletti
Condition: Schizophrenia

View study

CompletedNCT00460512

An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia

This study is completed. It focuses on schizophrenia and currently lists study information in Belgium, Bulgaria, Croatia, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Latvia, Lithuania, the Netherlands, Poland, Portugal, Russian Federation, Serbia, Spain, Sweden, Switzerland, Turkey, and the United Kingdom.

SchizophreniaOtherOver 18 Years

Countries: Belgium, Bulgaria, Croatia, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Latvia, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Serbia, Spain, Sweden, Switzerland, Turkey, United Kingdom
Sponsor: Janssen-Cilag International NV
Condition: Schizophrenia

View study

CompletedNCT03809325

A Survey to Collect Treatment Experience Feedback From Patients, Physicians, Nurses and Carers After Switching to Paliperidone Palmitate 3-monthly

This study is completed. It focuses on schizophrenia and currently lists study information in Belgium, France, Germany, Hungary, Italy, Spain, and the United Kingdom.

SchizophreniaOtherOver 18 Years

Countries: Belgium, France, Germany, Hungary, Italy, Spain, United Kingdom
Sponsor: Janssen-Cilag International NV
Condition: Schizophrenia

View study

CompletedNCT04787302

PET Trial to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

This study is completed. It focuses on schizophrenia and currently lists study information in Belgium and the United States.

SchizophreniaOtherFrom 18 Years to 55 Years

Countries: Belgium, United States
Sponsor: Cerevel Therapeutics, LLC
Condition: Schizophrenia

View study

TerminatedNCT01328093

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

This study has public registry information. It focuses on schizophrenia and currently lists study information in Austria, Belgium, France, Germany, Poland, the United States, Romania, Spain, and Sweden.

SchizophreniaOtherFrom 18 Years to 65 Years

Countries: Austria, Belgium, France, Germany, Poland, United States, Romania, Spain, Sweden
Sponsor: Denovo Biopharma LLC
Condition: Schizophrenia

View study

CompletedNCT04333797

Psychiatry of Transition in a World in Transition

This study is completed. It focuses on mental health and currently lists study information in Belgium.

Mental healthOtherFrom 17 Years to 17 Years

Countries: Belgium
Sponsor: Queen Fabiola Children's University Hospital
Condition: Mental health

View study

CompletedNCT04148508

App-based Mental Health Promotion in Young European Adults

This study is completed. It focuses on mental health and currently lists study information in Belgium, Germany, Spain, and the United Kingdom.

Mental healthOtherFrom 16 Years to 22 Years

Countries: Belgium, Germany, Spain, United Kingdom
Sponsor: University of Exeter
Condition: Mental health

View study

CompletedNCT04085172

A Study of TAK-503 in Children and Teenagers With Attention Deficit Hyperactivity Disorder (ADHD)

This study is completed. It focuses on ADHD and currently lists study information in Austria, Belgium, Germany, the Netherlands, Portugal, Spain, Sweden, the United Kingdom, and the United States.

ADHDOtherFrom 6 Years to 17 Years

Countries: Austria, Belgium, Germany, Netherlands, Portugal, Spain, Sweden, United Kingdom, United States
Sponsor: Shire
Condition: ADHD

View study

CompletedNCT04723719

Sleep IntervEntion as Symptom Treatment for ADHD

This study is completed. It focuses on ADHD and currently lists study information in Belgium.

ADHDOtherFrom 13 Years to 17 Years

Countries: Belgium
Sponsor: Universitaire Ziekenhuizen KU Leuven
Condition: ADHD

View study

WithdrawnNCT01913912

Event Rate and Effects of Stimulants in ADHD

This study has public registry information. It focuses on ADHD and currently lists study information in Belgium.

ADHDOtherFrom 7 Years to 12 Years

Countries: Belgium
Sponsor: University Ghent
Condition: ADHD

View study

CompletedNCT01500694

Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe

This study is completed. It focuses on ADHD and currently lists study information in Austria, Belgium, France, Germany, Ireland, Italy, the Netherlands, Poland, Romania, Spain, Sweden, Ukraine, and the United Kingdom.

ADHDOtherFrom 6 Years to 17 Years

Countries: Austria, Belgium, France, Germany, Ireland, Italy, Netherlands, Poland, Romania, Spain, Sweden, Ukraine, United Kingdom
Sponsor: Shire
Condition: ADHD

View study

CompletedNCT00763971

Randomized, Double-blind Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Children and Adolescents Aged 6-17

This study is completed. It focuses on ADHD and currently lists study information in Belgium, France, Germany, Hungary, Italy, the Netherlands, Poland, Spain, Sweden, and the United Kingdom.

ADHDOtherFrom 6 Years to 17 Years

Countries: Belgium, France, Germany, Hungary, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom
Sponsor: Shire
Condition: ADHD

View study

CompletedNCT01081145

Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD)

This study is completed. It focuses on ADHD and currently lists study information in Belgium, Canada, France, Germany, Italy, the Netherlands, Spain, Sweden, the United Kingdom, and the United States.

ADHDOtherFrom 6 Years to 17 Years

Countries: Belgium, Canada, France, Germany, Italy, Netherlands, Spain, Sweden, United Kingdom, United States
Sponsor: Shire
Condition: ADHD

View study

CompletedNCT01106430

Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylphenidate

This study is completed. It focuses on ADHD and currently lists study information in Belgium, Canada, Germany, Hungary, Italy, Poland, Spain, Sweden, the United Kingdom, and the United States.

ADHDOtherFrom 6 Years to 17 Years

Countries: Belgium, Canada, Germany, Hungary, Italy, Poland, Spain, Sweden, United Kingdom, United States
Sponsor: Shire
Condition: ADHD

View study

CompletedNCT01328756

Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)

This study is completed. It focuses on ADHD and currently lists study information in Belgium, Germany, Hungary, Italy, the Netherlands, Poland, Romania, Spain, Sweden, and the United Kingdom.

ADHDOtherFrom 6 Years to 17 Years

Countries: Belgium, Germany, Hungary, Italy, Netherlands, Poland, Romania, Spain, Sweden, United Kingdom
Sponsor: Shire
Condition: ADHD

View study

CompletedNCT00784654

Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17

This study is completed. It focuses on ADHD and currently lists study information in Belgium, France, Germany, Hungary, Italy, Poland, Sweden, the United Kingdom, and the United States.

ADHDOtherFrom 6 Years to 17 Years

Countries: Belgium, France, Germany, Hungary, Italy, Poland, Sweden, United Kingdom, United States
Sponsor: Shire
Condition: ADHD

View study

CompletedNCT02700685

Effect of Pycnogenol® on ADHD

This study is completed. It focuses on ADHD and currently lists study information in Belgium.

ADHDOtherFrom 6 Years to 12 Years

Countries: Belgium
Sponsor: Nina Hermans
Condition: ADHD

View study

CompletedNCT01338818

Open-label Extension Evaluating Methylphenidate Hydrochloride Extended Release in Adults With Attention Deficit/Hyperactivity Disorder

This study is completed. It focuses on ADHD and currently lists study information in Belgium, Colombia, Denmark, Germany, Sweden, and the United States.

ADHDOtherFrom 18 Years to 60 Years

Countries: Belgium, Colombia, Denmark, Germany, Sweden, United States
Sponsor: Novartis Pharmaceuticals
Condition: ADHD

View study

CompletedNCT01259492

Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)

This study is completed. It focuses on ADHD and currently lists study information in Belgium, Colombia, Denmark, Germany, Norway, Singapore, South Africa, Sweden, and the United States.

ADHDOtherFrom 18 Years to 60 Years

Countries: Belgium, Colombia, Denmark, Germany, Norway, Singapore, South Africa, Sweden, United States
Sponsor: Novartis Pharmaceuticals
Condition: ADHD

View study